Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of Pregnyl® when
given in combination with standard immunosuppressive therapy in pediatric and adult patients
with high-risk (Arm 1) or refractory/dependent (Arm 2) aGVHD.